AMAG Pharmaceuticals, Inc. (AMAG) Financial Statements (2024 and earlier)

Company Profile

Business Address 1100 WINTER STREET
WALTHAM, MA 02451
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments147,115124,743171,751191,544261,044266,510
Cash and cash equivalents98,52154,455113,009119,800150,461137,917
Short-term investments48,59470,28858,74271,744110,583128,593
Receivables65,104106,48494,16377,58883,18383,334
Inventory, net of allowances, customer advances and progress billings30,38833,67631,55328,64425,17929,664
Inventory30,38833,67631,55328,64425,17929,664
Other undisclosed current assets20,95025,73419,10043,06324,54940,567
Total current assets:263,557290,637316,567340,839393,955420,075
Noncurrent Assets
Operating lease, right-of-use asset22,00722,83523,2866,6426,582 
Property, plant and equipment3,0313,3124,1167,9128,2248,995
Intangible assets, net (including goodwill)426,459436,296446,133610,090614,302635,603
Goodwill422,513422,513422,513422,513422,513422,513
Intangible assets, net (excluding goodwill)3,94613,78323,620187,577191,789213,090
Restricted cash and investments495495495495495495
Deferred income tax assets   630630630 
Other noncurrent assets    1229
Other undisclosed noncurrent assets      7,654
Total noncurrent assets:451,992462,938474,660625,769630,245652,776
TOTAL ASSETS:715,549753,575791,227966,6081,024,2001,072,851
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities157,511184,181210,403198,839241,157177,222
Accounts payable12,94416,52027,02126,55426,94621,535
Accrued liabilities144,567167,661183,382172,285214,211155,687
Deferred revenue   1,1281,128 
Debt  4,065 3,9943,889 
Business combination, contingent consideration, liability   17113128118
Contract with customer, liability2,112
Other undisclosed current liabilities3,488 4,077  3,529
Total current liabilities:160,999188,246214,497204,074246,302182,981
Noncurrent Liabilities
Long-term debt and lease obligation304,400300,471296,825276,468272,809265,576
Long-term debt, excluding current maturities285,137281,038277,034273,124269,305265,576
Liabilities, other than long-term debt8281,120895,4385,5825,247
Deferred revenue   5,1715,171 
Contract with customer, liability4,288
Other liabilities8281,1208987228741
Operating lease, liability19,26319,43319,7913,3443,504 
Business combination, contingent consideration, liability    180183218
Other undisclosed noncurrent liabilities      4,328
Total noncurrent liabilities:305,228301,591296,914281,906278,391275,151
Total liabilities:466,227489,837511,411485,980524,693458,132
Equity
Equity, attributable to parent249,322263,738279,816480,628499,507614,719
Common stock344342339339339337
Additional paid in capital1,303,0951,300,5721,297,9171,292,4581,287,5531,282,284
Accumulated other comprehensive loss(2,964)(3,787)(3,239)(3,199)(3,032)(3,376)
Accumulated deficit(1,051,153)(1,033,389)(1,015,201)(808,970)(785,353)(664,526)
Total equity:249,322263,738279,816480,628499,507614,719
TOTAL LIABILITIES AND EQUITY:715,549753,575791,227966,6081,024,2001,072,851

Income Statement (P&L) ($ in thousands)

9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
Revenues52,75568,66188,50384,13178,10975,804
Cost of revenue
(Cost of Goods and Services Sold)
(18,180)(24,359)(43,322)(21,105)(24,290)(18,477)
Gross profit:34,57544,30245,18163,02653,81957,327
Operating expenses(41,584)(63,877)(240,327)(81,050)(169,662)(175,024)
Operating income (loss):(7,009)(19,575)(195,146)(18,024)(115,843)(117,697)
Nonoperating income (expense)(6,395)(4,816)(6,008)(5,361)(5,104)(4,524)
Investment income, nonoperating3274776358401,2241,586
Other nonoperating income (expense)(22)1,311130(45)2340
Interest and debt expense(6,700)(6,604)(6,510)(6,419)(6,330)(6,450)
Income (loss) from continuing operations before equity method investments, income taxes:(20,104)(30,995)(207,664)(29,804)(127,277)(128,671)
Other undisclosed income from continuing operations before income taxes   6,5106,4196,3306,450
Income (loss) from continuing operations before income taxes:(20,104)(30,995)(201,154)(23,385)(120,947)(122,221)
Income tax expense (benefit)160(100)21(232)120137
Income (loss) from continuing operations:(19,944)(31,095)(201,133)(23,617)(120,827)(122,084)
Income (loss) before gain (loss) on sale of properties:(19,944)(31,095)(201,133)(23,617)(120,827)(122,084)
Net income (loss):(19,944)(31,095)(201,133)(23,617)(120,827)(122,084)
Other undisclosed net income attributable to parent6,7006,604    
Net income (loss) available to common stockholders, diluted:(13,244)(24,491)(201,133)(23,617)(120,827)(122,084)

Comprehensive Income ($ in thousands)

9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
Net income (loss):(19,944)(31,095)(201,133)(23,617)(120,827)(122,084)
Comprehensive income (loss):(19,944)(31,095)(201,133)(23,617)(120,827)(122,084)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent7,5236,056(40)(167)344609
Comprehensive income (loss), net of tax, attributable to parent:(12,421)(25,039)(201,173)(23,784)(120,483)(121,475)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: